Gilde Healthcare announces successful pricing of Nasdaq IPO of portfolio company, Lava Therapeutics - Gilde Healthcare

Gilde Healthcare announces successful pricing of Nasdaq IPO of portfolio company, Lava Therapeutics

March 25, 2021

Utrecht, the Netherlands – Gilde Healthcare, a specialized healthcare investor with $1.8 billion under management, today announced that its portfolio company, LAVA Therapeutics (Nasdaq: LVTX), has successfully achieved pricing of its Nasdaq initial public offering (IPO), expected to result in gross proceeds of approximately $100 million. LVTX shares are expected to begin trading on March 25, 2021.

LAVA is a biotechnology company focused on transforming cancer treatment by developing a platform of novel bispecific antibodies engineered to selectively induce gamma-delta T cell-mediated immunity against tumor cells.

Gilde Healthcare has played an active role in LAVA’s maturation as it progressed to its IPO. Gilde Healthcare acted as the lead investor in the first institutional investment round of €16M in LAVA in 2018 and has been the only Dutch institutional shareholder to date. Additionally, Gilde Healthcare’s Operational Partner Prof. Dr. Paul Parren is Executive Vice President and Head of R&D of LAVA. Gilde Healthcare also has been instrumental in relocating LAVA´s headquarters and labs to the Utrecht Science Park, establishing a US subsidiary, hiring key management and taking part in the $83 million Series C financing together with other leading investors.

Stefan Luzi, Partner at Gilde Healthcare and Member of the LAVA Board of Directors, commented:

“We are proud to have been purposefully involved in the growth of LAVA from its first institutional investment round to its NASDAQ IPO in just 3 years. LAVA represents a clear case study in how we can contribute, above and beyond providing financial resources, and will serve as a model, which we aim to replicate for other differentiated healthcare companies.”

Gilde Healthcare is a specialized healthcare investor with $1.8 billion under management across two fund strategies: Venture & Growth and Private Equity. The firm operates out of offices in Utrecht (The Netherlands), Frankfurt (Germany) and Cambridge (United States).

Gilde Healthcare Venture & Growth invests in innovative companies active in (Bio)Pharmaceuticals, HealthTech and MedTech. The portfolio of the Venture & Growth fund is balanced with fast growing life science companies from Europe and North America.

For more information, please visit www.gildehealthcare.com.

Investor & Media Contact
Chris Maggos
LifeSci Advisors
+41 79 367 6254
chris@lifesciadvisors.com

More news

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
October 17, 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
October 15, 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
October 14, 2025